AstraZeneca’s triple-combination therapy for people with chronic obstructive pulmonary disease (COPD) has been approved in China as a maintenance treatment. The therapy comprises three compounds: the corticosteroid budesonide, and two long-acting bronchodilators — glycopyrronium, a muscarinic antagonist, and formoterol fumarate, a β2-agonist. This combo…
Using e-cigarettes significantly increases the risk of developing chronic lung diseases like asthma, bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD), a study found. Dual users — those who smoke tobacco and use e-cigarettes — are at an even higher risk than people with only one of these habits.
The use of Propeller Health’s digital health program, which integrates real-time data from chronic obstructive pulmonary disease (COPD) patients and feedback from healthcare providers, had a significant improvement on health outcomes, a new study shows. The study, “Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in…
CSA Medical‘s RejuvenAir System has been granted CE Mark approval in Europe for treating people with chronic obstructive pulmonary disease (COPD) who have chronic bronchitis — frequent inflammation of the bronchial airways. RejuvenAir is a cryosurgical medical device designed to destroy cells on the surface of the…
The Global Initiative for Chronic Obstructive Disease (GOLD) recommends the use of endobronchial valves — such as the Zephyr Valve — for bronchoscopic lung volume reduction (BLVR) as a standard treatment for people with emphysema or less severe forms of chronic obstructive pulmonary disease (COPD). GOLD considers there…
November is National Chronic Obstructive Pulmonary Disease (COPD) Awareness Month, and to recognize it and the people with this disease, the testing laboratory EMSL Analytical reminded patients of indoor air quality pollutants, irritants, and allergens that can aggravate their condition. According to EMSL, indoor air pollutants and allergens that…
The criteria used to diagnose chronic obstructive pulmonary disease (COPD) should be expanded beyond measurements of lung function, a new study suggests. The study, “COPDGene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease,” was published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD…
AlphaID, a cheek swab test that can help identify patients with chronic obstructive pulmonary disease (COPD) who have the disease due to alpha-1 antitrypsin deficiency (AATD), is now available for use by U.S. physicians and healthcare providers. AATD, which also is known as hereditary pulmonary emphysema, is…
A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including chronic obstructive pulmonary disease (COPD), so to better predict a patient’s likely response to treatment and likely disease progression. The…
A new national report from the Ontario Lung Association (OLA) highlights significant knowledge gaps about chronic obstructive pulmonary disease, or COPD that often prevent Canadians with the inflammatory disease from being properly diagnosed and treated. Called “Helping the Missing Million,” the national report was based on…
Get regular updates to your inbox.
